# OnCo record breast-hr-positive (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/breast-hr-positive/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "breast-hr-positive" ;
  schema:name "HR-positive / HER2-negative breast cancer"@en ;
  schema:description "HR-positive breast cancer is the most common breast cancer, driven by oestrogen. It was treated for years with hormone-blocking pills, now joined by CDK4/6 inhibitors, PI3K-pathway drugs, degraders, and ADCs."@en ;
  schema:url <https://onco.cc/cancers/breast-hr-positive/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Breast_cancer> ;
  owl:sameAs <http://www.wikidata.org/entity/Q128581> ;
  schema:citation <https://en.wikipedia.org/wiki/Breast_cancer> ;
  onco:tag "breast", "spike" ;
  onco:related <https://onco.cc/roadmaps/adc-generations/>, <https://onco.cc/roadmaps/trop2-adc-roadmap/>, <https://onco.cc/pairings/oral-serd-plus-cdk46-after-esr1/>, <https://onco.cc/pairings/pi3k-pathway-plus-endocrine/>, <https://onco.cc/pairings/genomic-assay-to-chemo-omission/>, <https://onco.cc/pairings/cdk46-plus-endocrine/>, <https://onco.cc/cancers/breast-her2-positive/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/her2-low-metastatic-breast-cancer/>, <https://onco.cc/cancers/male-breast-cancer/>, <https://onco.cc/cancers/ductal-carcinoma-in-situ/> ;
  onco:technologies <https://onco.cc/technologies/endocrine-therapy/>, <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/technologies/protac-degrader/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/digital-pathology-ai/>, <https://onco.cc/technologies/mammography/>, <https://onco.cc/technologies/acupuncture-aromatase-inhibitor-arthralgia/>, <https://onco.cc/technologies/acupuncture-hot-flushes/>, <https://onco.cc/technologies/hypnosis-cancer-care/>, <https://onco.cc/technologies/dance-movement-therapy/>, <https://onco.cc/technologies/peer-support-groups/>, <https://onco.cc/technologies/lymphoedema-decongestive-therapy/>, <https://onco.cc/technologies/shark-cartilage/>, <https://onco.cc/technologies/mrd-testing/>, <https://onco.cc/technologies/rna-seq/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/exercise-oncology/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/>, <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/akt/>, <https://onco.cc/targets/her2/>, <https://onco.cc/targets/trop2/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/her3/> ;
  onco:drugs <https://onco.cc/drugs/guardant360-cdx/>, <https://onco.cc/drugs/therascreen-cdx/>, <https://onco.cc/drugs/her2-testing-assays/>, <https://onco.cc/drugs/caris-mi-cancer-seek/>, <https://onco.cc/drugs/lunit-insight-mmg/>, <https://onco.cc/drugs/epirubicin/>, <https://onco.cc/drugs/ixabepilone/>, <https://onco.cc/drugs/megestrol/>, <https://onco.cc/drugs/thiotepa/>, <https://onco.cc/drugs/toremifene/>, <https://onco.cc/drugs/raloxifene/>, <https://onco.cc/drugs/triptorelin/>, <https://onco.cc/drugs/dexrazoxane/>, <https://onco.cc/drugs/talc-sclerosant/>, <https://onco.cc/drugs/samarium-153-lexidronam/>, <https://onco.cc/drugs/ibandronic-acid/>, <https://onco.cc/drugs/anastrozole/> ;
  onco:companies <https://onco.cc/companies/oncolytics-biotech/>, <https://onco.cc/companies/shenzhen-ionova-life-sciences/>, <https://onco.cc/companies/treadwell-therapeutics/>, <https://onco.cc/companies/forward-pharmaceuticals/>, <https://onco.cc/companies/mbrace-therapeutics/>, <https://onco.cc/companies/olema-pharmaceuticals/>, <https://onco.cc/companies/astrazeneca/>, <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/novartis/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/menarini/>, <https://onco.cc/companies/arvinas/>, <https://onco.cc/companies/celcuity/>, <https://onco.cc/companies/gilead/>, <https://onco.cc/companies/daiichi-sankyo/>, <https://onco.cc/companies/exact-sciences/> ;
  onco:pathways <https://onco.cc/pathways/er-signaling/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/breast-cancer-signalling/> ;
  onco:terms <https://onco.cc/terms/esr1-mutation/>, <https://onco.cc/terms/oral-serd/>, <https://onco.cc/terms/endocrine-resistance/>, <https://onco.cc/terms/ovarian-function-suppression/>, <https://onco.cc/terms/late-recurrence/>, <https://onco.cc/terms/her2-low/>, <https://onco.cc/terms/ctdna/> ;
  onco:trials <https://onco.cc/trials/monaleesa-2/>, <https://onco.cc/trials/monarch-3/>, <https://onco.cc/trials/paloma-2/>, <https://onco.cc/trials/solar-1/>, <https://onco.cc/trials/capitello-291/>, <https://onco.cc/trials/inavo120/>, <https://onco.cc/trials/emerald/>, <https://onco.cc/trials/ember-3/>, <https://onco.cc/trials/serena-6/>, <https://onco.cc/trials/evera/>, <https://onco.cc/trials/persevera/>, <https://onco.cc/trials/lidera/>, <https://onco.cc/trials/postmonarch/>, <https://onco.cc/trials/tailorx/>, <https://onco.cc/trials/rxponder/>, <https://onco.cc/trials/soft-text/>, <https://onco.cc/trials/pallas-penelope-b/>, <https://onco.cc/trials/tropics-02/>, <https://onco.cc/trials/fourlight-1/>, <https://onco.cc/trials/cambria/>, <https://onco.cc/trials/tmist/>, <https://onco.cc/trials/nct07003074/>, <https://onco.cc/trials/nct06561607/>, <https://onco.cc/trials/nct07008976/>, <https://onco.cc/trials/nct07043725/>, <https://onco.cc/trials/nct07354022/>, <https://onco.cc/trials/nct07024173/>, <https://onco.cc/trials/nct07349069/>, <https://onco.cc/trials/nct05744687/>, <https://onco.cc/trials/nct05860465/>, <https://onco.cc/trials/nct07461454/>, <https://onco.cc/trials/nct05780567/>, <https://onco.cc/trials/nct05365178/>, <https://onco.cc/trials/nct06079983/>, <https://onco.cc/trials/nct05077449/>, <https://onco.cc/trials/nct07062965/>, <https://onco.cc/trials/nct06383767/>, <https://onco.cc/trials/nct06998108/>, <https://onco.cc/trials/nct07207070/>, <https://onco.cc/trials/pik3ca-2/>, <https://onco.cc/trials/nct05232916/>, <https://onco.cc/trials/nct06954961/>, <https://onco.cc/trials/simrise/>, <https://onco.cc/trials/nct06982521/>, <https://onco.cc/trials/nct05346224/>, <https://onco.cc/trials/nct07386938/>, <https://onco.cc/trials/nct07492641/>, <https://onco.cc/trials/nct07413939/>, <https://onco.cc/trials/start-b/>, <https://onco.cc/trials/prime-ii/>, <https://onco.cc/trials/lumina/>, <https://onco.cc/trials/import-low/>, <https://onco.cc/trials/nsabp-b39/>, <https://onco.cc/trials/eortc-22922/>, <https://onco.cc/trials/ma-20/>, <https://onco.cc/trials/dbcg-82bc/>, <https://onco.cc/trials/nct03725059/>, <https://onco.cc/trials/nct06065748/>, <https://onco.cc/trials/nct05840211/>, <https://onco.cc/trials/nct06016738/>, <https://onco.cc/trials/nct02107703/>, <https://onco.cc/trials/nct05646862/>, <https://onco.cc/trials/nct07085767/>, <https://onco.cc/trials/nct00099437/>, <https://onco.cc/trials/nct04711252/>, <https://onco.cc/trials/nct06112379/>, <https://onco.cc/trials/nct05587296/>, <https://onco.cc/trials/nct06757634/>, <https://onco.cc/trials/nct05038735/>, <https://onco.cc/trials/nct05950945/>, <https://onco.cc/trials/nct06380751/>, <https://onco.cc/trials/nct07647328/>, <https://onco.cc/trials/nct06760637/>, <https://onco.cc/trials/nct06790693/>, <https://onco.cc/trials/nct07205822/> ;
  onco:people <https://onco.cc/people/murray-brunt/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-predimed-breast-jama-im-2015/>, <https://onco.cc/key-papers/paper-brca-risk-reducing-surgery-jama-2010/> ;
  onco:journals <https://onco.cc/journals/breast-cancer-jbcs/>, <https://onco.cc/journals/breast-cancer-research/>, <https://onco.cc/journals/breast-cancer-research-and-treatment/>, <https://onco.cc/journals/clinical-breast-cancer/>, <https://onco.cc/journals/journal-of-breast-imaging/>, <https://onco.cc/journals/journal-of-mammary-gland-biology-and-neoplasia/>, <https://onco.cc/journals/the-breast/>, <https://onco.cc/journals/the-breast-journal/> ;
  onco:pipeline <https://onco.cc/drugs/vepdegestrant/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/artera-ai-breast/>, <https://onco.cc/drugs/patritumab-deruxtecan/>, <https://onco.cc/drugs/tqb2102/>, <https://onco.cc/drugs/hrs-8080/>, <https://onco.cc/drugs/ipatasertib/>, <https://onco.cc/drugs/rc148/>, <https://onco.cc/drugs/sph4336/>, <https://onco.cc/drugs/yl202/>, <https://onco.cc/drugs/tqb3616/>, <https://onco.cc/drugs/jskn003/>, <https://onco.cc/drugs/kn026/>, <https://onco.cc/drugs/gotistobart/>, <https://onco.cc/drugs/xzp-3287/>, <https://onco.cc/drugs/pf-07248144/>, <https://onco.cc/drugs/esg401/>, <https://onco.cc/drugs/evorpacept/>, <https://onco.cc/drugs/bebt-209/>, <https://onco.cc/drugs/js105/>, <https://onco.cc/drugs/jskn016/>, <https://onco.cc/drugs/hlx22/>, <https://onco.cc/drugs/tersolisib/>, <https://onco.cc/drugs/glsi-100/>, <https://onco.cc/drugs/d-0502/>, <https://onco.cc/drugs/sim0270/>, <https://onco.cc/drugs/zovegalisib/>, <https://onco.cc/drugs/hlx11/>, <https://onco.cc/drugs/rph-051/>, <https://onco.cc/drugs/bgb-43395/>, <https://onco.cc/drugs/ro7771950/>, <https://onco.cc/drugs/tqb2930/>, <https://onco.cc/drugs/avzo-021/>, <https://onco.cc/drugs/serabelisib/>, <https://onco.cc/drugs/sapanisertib/>, <https://onco.cc/drugs/jk08/>, <https://onco.cc/drugs/ep0062/>, <https://onco.cc/drugs/env-501/>, <https://onco.cc/drugs/sys6023/>, <https://onco.cc/drugs/samuraciclib/>, <https://onco.cc/drugs/camizestrant/>, <https://onco.cc/drugs/giredestrant/>, <https://onco.cc/drugs/atirmociclib/>, <https://onco.cc/trials/cambria/>, <https://onco.cc/trials/fourlight-1/>, <https://onco.cc/trials/lidera/>, <https://onco.cc/trials/evera/>, <https://onco.cc/drugs/imlunestrant/>, <https://onco.cc/drugs/gedatolisib/>, <https://onco.cc/ideas/idea-ctdna-switch-generalised/>, <https://onco.cc/ideas/idea-cdk4-selective-first-line/>, <https://onco.cc/ideas/idea-late-recurrence-interception/>, <https://onco.cc/technologies/mrd-testing/> ;
  onco:standardOfCare <https://onco.cc/drugs/oncotype-dx/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/trials/monarche/>, <https://onco.cc/trials/natalee/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/drugs/inavolisib/>, <https://onco.cc/drugs/elacestrant/>, <https://onco.cc/drugs/vepdegestrant/>, <https://onco.cc/drugs/gedatolisib/>, <https://onco.cc/trials/destiny-breast06/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/technologies/mammography/>, <https://onco.cc/technologies/radiology-ai-screening/>, <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/trials/tailorx/>, <https://onco.cc/trials/rxponder/>, <https://onco.cc/drugs/oncotype-dx/>, <https://onco.cc/drugs/mammaprint/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/tamoxifen/>, <https://onco.cc/drugs/goserelin/>, <https://onco.cc/trials/soft-text/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/trials/monarche/>, <https://onco.cc/trials/natalee/>, <https://onco.cc/trials/pallas-penelope-b/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/lidera/>, <https://onco.cc/trials/cambria/>, <https://onco.cc/drugs/giredestrant/>, <https://onco.cc/trials/monaleesa-2/>, <https://onco.cc/trials/monarch-3/>, <https://onco.cc/trials/paloma-2/>, <https://onco.cc/trials/inavo120/>, <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/inavolisib/>, <https://onco.cc/trials/serena-6/>, <https://onco.cc/drugs/camizestrant/>, <https://onco.cc/trials/ember-3/>, <https://onco.cc/trials/emerald/>, <https://onco.cc/trials/veritac-2/>, <https://onco.cc/trials/capitello-291/>, <https://onco.cc/trials/solar-1/>, <https://onco.cc/drugs/gedatolisib/>, <https://onco.cc/trials/evera/>, <https://onco.cc/trials/postmonarch/>, <https://onco.cc/drugs/elacestrant/>, <https://onco.cc/drugs/imlunestrant/>, <https://onco.cc/drugs/vepdegestrant/>, <https://onco.cc/drugs/capivasertib/>, <https://onco.cc/trials/destiny-breast06/>, <https://onco.cc/trials/destiny-breast04/>, <https://onco.cc/trials/tropics-02/>, <https://onco.cc/trials/tropion-breast01/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/sacituzumab-govitecan/>, <https://onco.cc/drugs/datopotamab-deruxtecan/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/technologies/exercise-oncology/>, <https://onco.cc/technologies/cardio-oncology/> .